A medical device startup company, developing a breakthrough solution for transcatheter mitral valve replacement.

The Challenges

TMVR poses new challenges in comparison with TAVI:

  • Robust anchoring of the valve to the native annulus

  • Implantation in a minimally invasive approach – transcatheter

  • Creation of a simple and safe procedure

  • Elimination of paravalvular leaks (PVL)

  • Elimination of Left Ventricular Outflow Tract (LVOT) obstruction

  • Minimization of disturbance to the cardiac structure

  • Large valve area and high work blood pressures

  • Valve prosthesis durability

Successful Pre-Clinical Study

TruLeaf Medical has recently completed a successful animal trial in porcine model. 

As part of the development process, the study was performed in order to demonstrate the safety and performance of the system, for an extensive time period.

See on the left: one of many successful implantations. 

In The News

A Market of 15B USD a Year Awaits Revolutionary Israelis

August 14, 2022

After revolutionizing heart catheterization procedures in the world, the Israeli engineers want to do it again – and this time they are turning to the heart valve market, which is estimated at about 15 billion dollars a year in the US alone. TruLeaf announces it has completed the development of its revolutionary valve prosthesis

(Article below in Hebrew)

See full article here

TruLeaf Medical’s Successful Mitral Valve Replacement Large Animals Clinical Trial Proves the Accurate Deployment and Long-term Functioning of the Implants in the Heart

May 13, 2020

Allium Medical (TASE: ALMD), an Israeli medical device company, specializes in minimally invasive technologies subsidiary, TruLeaf Medical, has successfully tested a novel approach for transcatheter mitral valve replacement in patients suffering from severe mitral valve regurgitation during a long-term trial on large animals.

See full article here

TruLeaf Medical raises additional 5M NIS from the Israeli Innovation Authority

April 5, 2020

TruLeaf Medical has received a 5M NIS grant from the Israeli Innovation Authority. This grant follows an additional 2.6M NIS grant received during the month of March 2020.
The grant was approved for the continuation of development of a minimally invasive trans catheter mitral valve replacement. TruLeaf, a daughter company of Allium Medical, is developing a system for the replacement of the mitral valve in patients suffering from severe mitral regurgitation, inserted using catheterization techniques. 
The grant will be used for furthering the R&D activities, TruLeaf’s IP and design freeze towards a first clinical study in human patients.